CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Pharming Group Publishes Q3 2026 Results Call Transcript

By Public Technologies
  • Pharming’s October 27, 2026, third-quarter results call featured interim co-CEOs Kenneth Lynard and Leverne Marsh alongside Chief Medical Officer Anurag Relan.
  • Management narrowed full-year revenue guidance to USD 380 million–390 million; operating expense guidance fell to USD 310 million–315 million.
  • Quarterly revenue rose 21% to USD 117.6 million, supported by RUCONEST’s return to growth.
  • Early inventory building contributed 9 percentage points of RUCONEST’s 14% growth, potentially affecting fourth-quarter revenue.
  • Leniolisib’s CVID trial results are expected in November, informing a potential Phase III study following positive genetic immunodeficiency data.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharming Group NV published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk